Agios Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGIO research report →
About the company
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias.
- CEO
- Brian Goff
- IPO
- 2013
- Employees
- 486
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $2.23B
- P/E
- -5.18
- P/S
- 33.84
- P/B
- 1.99
- EV/EBITDA
- -5.16
- Div Yield
- 0.00%
- Gross Margin
- 82.07%
- Op Margin
- -719.97%
- Net Margin
- -639.84%
- ROE
- -34.11%
- ROIC
- -41.43%
- Revenue
- $54.03M · 48.03%
- Net Income
- $-412,781,000 · -161.27%
- EPS
- $-7.12 · -160.03%
- Op Income
- $-472,132,000
- FCF YoY
- 3.64%
- 52W High
- $46.00
- 52W Low
- $22.24
- 50D MA
- $29.84
- 200D MA
- $31.74
- Beta
- 0.59
- Avg Volume
- 1.13M
Get TickerSpark's AI analysis on AGIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Gheuens Sarah | other | 8,375 |
| Jul 1, 26 | Gheuens Sarah | sell | 4,007 |
| Jul 1, 26 | Gheuens Sarah | other | 8,375 |
| Jun 18, 26 | Ballal Rahul D. | other | 2,816 |
| Jun 18, 26 | Ballal Rahul D. | other | 14,950 |
| Jun 18, 26 | Ballal Rahul D. | other | 2,927 |
| Jun 18, 26 | Ballal Rahul D. | other | 2,816 |
| Jun 18, 26 | CAPELLO JEFFREY D | other | 14,950 |
| Jun 18, 26 | CAPELLO JEFFREY D | other | 2,816 |
| Jun 18, 26 | CAPELLO JEFFREY D | other | 2,927 |
Our AGIO coverage
Recent articles, reports, and earnings notes.
No research on AGIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AGIO report →Similar companies
Peers in the same neighborhood.